165 related articles for article (PubMed ID: 29088451)
41. [Progressive systemic scleroderma complicated by localized morphea].
Konishi T; Yamao T; Wada J; Kusudo K; Fujita T
Nihon Rinsho; 1974 Dec; 32(12):3613-9. PubMed ID: 4477212
[No Abstract] [Full Text] [Related]
42. Paraneoplastic Systemic Sclerosis: Focus on Anti-RNA Polymerase III Antibodies.
Heymann WR
Skinmed; 2016; 14(1):39-40. PubMed ID: 27072728
[No Abstract] [Full Text] [Related]
43. Histological and rheological grading of cutaneous sclerosis in scleroderma.
Piérard GE
Dermatologica; 1989; 179(1):18-20. PubMed ID: 2767293
[TBL] [Abstract][Full Text] [Related]
44. Localized and systemic scleroderma.
Hawk A; English JC
Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
[TBL] [Abstract][Full Text] [Related]
45. [HLA antigen frequencies in patients with progressive systemic sclerosis and morphea (author's transl)].
Freudenberg J; Holzmann H; Schneider S; Korting GW
Arch Dermatol Res; 1978 Nov; 263(2):197-205. PubMed ID: 736604
[TBL] [Abstract][Full Text] [Related]
46. Anti-phosphatidylserine-prothrombin complex antibodies in patients with localized scleroderma.
Hasegawa M; Fujimoto M; Hayakawa I; Matsushita T; Nishijima C; Yamazaki M; Takehara K; Sato S
Clin Exp Rheumatol; 2006; 24(1):19-24. PubMed ID: 16539814
[TBL] [Abstract][Full Text] [Related]
47. Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment.
Dall'Ara F; Lazzaroni MG; Antonioli CM; Airò P
Rheumatol Int; 2017 May; 37(5):847-851. PubMed ID: 28160072
[TBL] [Abstract][Full Text] [Related]
48. [Disseminated circumscribed acleroderma associated with diffuse scleroderma of an acrosclerotic type].
Ryckmanns F; Konz B
Hautarzt; 1980 Feb; 31(2):86-90. PubMed ID: 7399900
[TBL] [Abstract][Full Text] [Related]
49. Demographic differences in the frequencies of scleroderma-related autoantibodies.
Picillo U; Migliaresi S; Vatti M; Marcialis MR; Ferruzzi AM; Tirri G
Arthritis Rheum; 1993 Sep; 36(9):1332-4. PubMed ID: 8216429
[No Abstract] [Full Text] [Related]
50. Ichthyotic-appearing skin changes associated with childhood morphea, systemic sclerosis, and systemic lupus erythematosus/scleroderma overlap.
Williams CM; Storm CA; Burns C; Rigby W; Dinulos JG
Pediatr Dermatol; 2010; 27(2):170-3. PubMed ID: 20537069
[TBL] [Abstract][Full Text] [Related]
51. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
52. Mucin deposits in morphea and systemic scleroderma.
Rongioletti F; Gambini C; Micalizzi C; Pastorino A; Rebora A
Dermatology; 1994; 189(2):157-8. PubMed ID: 8075444
[TBL] [Abstract][Full Text] [Related]
53. [Morphea resembling pseudoxanthoma elasticum in progressive scleroderma].
Steigleder GK; Müller HD; Noack M
Z Hautkr; 1978 Dec; 53(23):829-33. PubMed ID: 726540
[TBL] [Abstract][Full Text] [Related]
54. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
[TBL] [Abstract][Full Text] [Related]
55. [Electron optic studies of the muscles in generalized and circumscribed scleroderma].
Jablońska S; Jakubowicz K; Biczysko W; Dabrowski J
Dermatol Monatsschr; 1970; 156(3):162-74. PubMed ID: 5512459
[No Abstract] [Full Text] [Related]
56. Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III.
Hirakata M; Okano Y; Pati U; Suwa A; Medsger TA; Hardin JA; Craft J
J Clin Invest; 1993 Jun; 91(6):2665-72. PubMed ID: 8390487
[TBL] [Abstract][Full Text] [Related]
57. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.
Terras S; Hartenstein H; Höxtermann S; Gambichler T; Kreuter A
Int J Dermatol; 2016 Aug; 55(8):882-5. PubMed ID: 26499848
[TBL] [Abstract][Full Text] [Related]
58. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
[TBL] [Abstract][Full Text] [Related]
59. Circulating immune complexes in systemic scleroderma and generalized morphea.
O'Loughlin S; Tappeiner G; Jordon RE
Dermatologica; 1980; 160(1):25-30. PubMed ID: 7351267
[TBL] [Abstract][Full Text] [Related]
60. Protective Effect Against Cancer of Antibodies to the Large Subunits of Both RNA Polymerases I and III in Scleroderma.
Shah AA; Laiho M; Rosen A; Casciola-Rosen L
Arthritis Rheumatol; 2019 Sep; 71(9):1571-1579. PubMed ID: 30888702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
